There are currently 7 active clinical trials seeking participants for Graft Versus Host Disease research studies. The states with the highest number of trials for Graft Versus Host Disease participants are New York, California, Massachusetts and Washington.
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
NCT03602599
Recruiting
Background: This study follows people who have had, or will soon have, a transplant using stem cells from another person. This is known as an allogeneic hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (cGVHD) can happen after HSCT. cGVHD can cause mouth problems and more serious issues. Researchers want to study changes in the mouth that might indicate cGVHD. Objective: To identify cGVHD in the mouth and better understand the development, treatment, and progress of post-t... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/11/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Graft Versus Host Disease
Register for Updates
Optimizing PTCy Dose and Timing
NCT03983850
Recruiting
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these risks. Researchers want to see if a lower dose of PTCy can have the same benefits. Based on encouraging results from the first part of the study, researchers now are investigating whether a lower dose of PTCy can allow other immunosuppression to be dec... Read More
Gender:
All
Ages:
Between 12 years and 120 years
Trial Updated:
06/08/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Register for Updates
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
NCT05263999
Recruiting
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids
Gender:
All
Ages:
12 years and above
Trial Updated:
06/07/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +105 locations
Conditions: Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
Register for Updates
Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
NCT06008808
Recruiting
Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readily available haploidentical donors. One of the risks of a haploidentical HCT is graft vs. host disease (GVHD), but it is difficult to reduce the incidence of GVHD without compromising the graft vs. leu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
Register for Updates
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
NCT04886726
Recruiting
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/03/2024
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Graft Versus Host Disease
Register for Updates
Detection of Graft Versus Host Disease With [18F]F-AraG
NCT03367962
Recruiting
This is a single-center imaging study to determine utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. [18F]F-AraG PET scans will be compared to biopsy results to correlate T cell accumulation which is implicated in the disease. High risk patients will be followed to verify predictive potential of [18F]F-AraG.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/03/2023
Locations: Stanford Hospital, Stanford, California
Conditions: Graft Versus Host Disease
Register for Updates
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
NCT05866302
Recruiting
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the ons... Read More
Gender:
All
Ages:
36 months and above
Trial Updated:
10/03/2023
Locations: Stanford Hospital, Stanford, California +5 locations
Conditions: Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
Register for Updates